Evogene (NASDAQ:EVGN) Releases Earnings Results, Misses Expectations By $0.33 EPS

Evogene (NASDAQ:EVGN) issued its earnings results on Wednesday. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33), FiscalAI reports. The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.35 million. Evogene had a negative net margin of 214.57% and a negative return on equity of 121.44%.

Evogene Stock Performance

Shares of EVGN stock opened at $0.73 on Wednesday. The firm’s 50-day moving average is $0.80 and its 200-day moving average is $0.96. The stock has a market cap of $6.37 million, a price-to-earnings ratio of -0.62 and a beta of 1.39. Evogene has a 52-week low of $0.70 and a 52-week high of $2.42.

Institutional Investors Weigh In On Evogene

A number of institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC raised its holdings in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares during the period. Jane Street Group LLC raised its holdings in Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,387 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Evogene during the fourth quarter worth approximately $25,000. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.